Project Grant R01AI075523

The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...

Federal Project Grant Award Summary Mapp Biopharmaceutical, Inc. received a $993,353 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 24, 2025, with performance through August 31, 2028. The grant funds development of MBP002, a fully human monoclonal antibody (mAb) product designed for respiratory syncytial virus (RSV) immunoprophylaxis in neonates and infants. MBP002 is...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Massachusetts General Hospital $364,484 through the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025, to support research on soluble guanylate cyclase (SGC) pathway activation as a novel bronchodilation strategy for respiratory syncytial virus (RSV) bronchiolitis in pediatric populations. The research project, with an ultimate completion date of June 30, 2027,...

Federal Project Grant Award Summary Inhalon Biopharma, Inc. received a $1,013,468 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 1, 2025, with completion targeted for July 31, 2028. The company is developing IN-003PI, a passive immunization therapeutic comprised of a pair of neutralizing monoclonal antibodies (mAbs) against human metapneumovirus (MPV) fusion proteins....

GRANT AWARD SUMMARY La Jolla Institute for Immunology received a $923,708 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2031. The institute will develop therapeutic monoclonal antibody (MAb) cocktails targeting New World arenaviruses, specifically Machupo and Junin viruses, which cause severe hemorrhagic fever with no currently available...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Vanderbilt University Medical Center a $3.3 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 11, 2025, to examine the real-world effectiveness and uptake of newly approved Respiratory Syncytial Virus (RSV) maternal vaccines and monoclonal antibodies. The research will assess comparative effectiveness, cost-effectiveness, safety, and...

Federal Grant Award Summary Seattle Children's Hospital, doing business as Seattle Children's Research Institute, received a $182,726 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning September 1, 2025, and concluding August 31, 2030. This Career Development Award, led by Dr. Sara Kim, a pediatric infectious diseases specialist, supports research to establish protective immune...

Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,000 Project Grant to the University of Texas at Dallas under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, through July 31, 2027. This research project develops innovative measurement methodologies to characterize the spatial distribution of chemicals and pathogens within bioaerosols, with particular focus on understanding how virus viability is affected by...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University $775,187 on August 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research project examining the impact of systemic immunosuppression on respiratory syncytial virus (RSV) antibody generation and effector functions following vaccination. The research will systematically study antibody responses to novel...

Federal Grant Award Summary Seattle Children's Research Institute received a $862,347 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded February 20, 2026, with an ultimate completion date of January 31, 2031. The award funds research to investigate the impact of respiratory syncytial virus (RSV) vaccination and preterm delivery on maternal RSV-specific peripheral and mucosal...